Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2018-05-04
DOI
10.3389/fimmu.2018.00977
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner
- (2017) Konstantinos Dimopoulos et al. Molecular Oncology
- NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia
- (2017) Anne-Sophie Chretien et al. Oncotarget
- Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia
- (2017) Anne-Sophie Chretien et al. Frontiers in Immunology
- NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML
- (2017) Anne-Sophie Chretien et al. OncoImmunology
- Defective NK Cells in Acute Myeloid Leukemia Patients at Diagnosis Are Associated with Blast Transcriptional Signatures of Immune Evasion
- (2015) Zena Khaznadar et al. JOURNAL OF IMMUNOLOGY
- Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
- (2015) Jan Krönke et al. NATURE
- Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma
- (2014) Shang-Yi Huang et al. ANNALS OF HEMATOLOGY
- Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21WAF1/Cip1-dependent mechanism independent of functional p53
- (2014) J.-F. Fecteau et al. BLOOD
- Acute myeloid leukemia impairs natural killer cells through the formation of a deficient cytotoxic immunological synapse
- (2014) Zena Khaznadar et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia
- (2014) K. Stringaris et al. HAEMATOLOGICA
- Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide
- (2014) Eric S. Fischer et al. NATURE
- Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity
- (2014) Anne-Sophie Chretien et al. Frontiers in Immunology
- High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone
- (2013) Daniel Heintel et al. BRITISH JOURNAL OF HAEMATOLOGY
- Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity
- (2013) Anita K. Gandhi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Humanized NOD-SCID IL2rg –/– mice as a preclinical model for cancer research and its potential use for individualized cancer therapies
- (2013) Qianjun Zhou et al. CANCER LETTERS
- Lenalidomide as a novel treatment of acute myeloid leukemia
- (2013) Yiming Chen et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q)
- (2013) V Sardnal et al. LEUKEMIA
- Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
- (2013) J. Kronke et al. SCIENCE
- The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
- (2013) G. Lu et al. SCIENCE
- A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission
- (2012) N. Vey et al. BLOOD
- High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance
- (2012) A. Broyl et al. BLOOD
- Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration
- (2012) Matthew Hoffmann et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
- (2012) A Lopez-Girona et al. LEUKEMIA
- Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion
- (2012) S Wei et al. ONCOGENE
- IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect
- (2011) D. M. Benson et al. BLOOD
- Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
- (2011) Y. X. Zhu et al. BLOOD
- Therapeutic Effect of Lenalidomide in a Novel Xenograft Mouse Model of Human Blastic NK Cell Lymphoma/Blastic Plasmacytoid Dendritic Cell Neoplasm
- (2011) A. Agliano et al. CLINICAL CANCER RESEARCH
- Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities
- (2011) L. Mollgard et al. HAEMATOLOGICA
- Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients
- (2011) Beatriz Sanchez-Correa et al. IMMUNOLOGY AND CELL BIOLOGY
- Molecular Mechanisms of Natural Killer Cell Activation
- (2011) Yenan T. Bryceson et al. Journal of Innate Immunity
- Innate or Adaptive Immunity? The Example of Natural Killer Cells
- (2011) E. Vivier et al. SCIENCE
- Natural Killer Cell Killing of Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia Blasts by Killer Cell Immunoglobulin-Like Receptor–Negative Natural Killer Cells after NKG2A and LIR-1 Blockade
- (2010) Robert Godal et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia
- (2010) T. A. Fehniger et al. BLOOD
- Lenalidomide down regulates the production of interferon-γ and the expression of inhibitory cytotoxic receptors of human Natural Killer cells
- (2010) Nicolas Dauguet et al. CELLULAR IMMUNOLOGY
- Dexamethasone Synergizes with Lenalidomide to Inhibit Multiple Myeloma Tumor Growth, But Reduces Lenalidomide-Induced Immunomodulation of T and NK Cell Function
- (2010) A. K. Gandhi et al. CURRENT CANCER DRUG TARGETS
- Dose Escalation of Lenalidomide in Relapsed or Refractory Acute Leukemias
- (2010) William Blum et al. JOURNAL OF CLINICAL ONCOLOGY
- Single-Agent Lenalidomide in the Treatment of Previously Untreated Chronic Lymphocytic Leukemia
- (2010) Christine I. Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44+) and T (HLA-DR+) cells
- (2009) M Lioznov et al. BONE MARROW TRANSPLANTATION
- Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors
- (2009) Miroslaw J. Szczepanski et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide
- (2009) S. Wei et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells
- (2008) L. Wu et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More